Reportedly, the Council of the European Union is considering member state objections and requests to extend the current scrutiny period beyond 4 December for a Commission delegated regulation that would classify titanium dioxide as a Category 2 carcinogen by inhalation. The move threatens to impact the marketing of sunscreens and other cosmetics in the EU that contain respirable TiO2 particles.
A European Commission delegated regulation classifying titanium dioxide as a Category 2 (“suspected”) carcinogen under the Classification, Labeling and Packaging (CLP) regulation is on track to apply by mid-2020.
The classification stands to impact marketers of sunscreens and other cosmetics containing respirable TiO2 particles – potentially including sunscreen sprays...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
